HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark W J Ferguson Selected Research

Transforming Growth Factor beta3 (TGF beta 3)

8/2009Avotermin for the improvement of scar appearance: a new pharmaceutical in a new therapeutic area.
4/2009Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies.
9/2008Avotermin: a novel antiscarring agent.
3/2007Temporal and spatial expression of Pax9 and Sonic hedgehog during development of normal mouse palates and cleft palates in TGF-beta3 null embryos.
10/2005Experimental manipulation of transforming growth factor-beta isoforms significantly affects adhesion formation in a murine surgical model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark W J Ferguson Research Topics

Disease

27Cicatrix (Scar)
01/2019 - 02/2003
23Wounds and Injuries (Trauma)
04/2012 - 05/2002
3Keloid
01/2006 - 02/2003
2Burns
01/2019 - 02/2010
2Hypertrophic Cicatrix (Hypertrophic Scar)
01/2005 - 02/2003
2Dupuytren Contracture (Dupuytrens Contracture)
01/2005 - 06/2003
2Fibrosis (Cirrhosis)
04/2004 - 02/2003
2Genetic Predisposition to Disease (Genetic Predisposition)
06/2003 - 02/2003
1Tendon Injuries
01/2014
1Necrosis
01/2012
1Primary Myelofibrosis (Myelosclerosis)
02/2010
1Pulmonary Fibrosis (Fibrosing Alveolitis)
02/2010
1Inflammation (Inflammations)
11/2009
1Erythema
04/2009
1Cleft Palate (Palate, Cleft)
03/2007
1Arteriosclerosis
04/2004

Drug/Important Bio-Agent (IBA)

11CollagenIBA
01/2019 - 01/2003
10Transforming Growth Factor beta (TGF-beta)IBA
04/2012 - 05/2002
9human TGFB3 proteinIBA
09/2011 - 09/2008
7Pharmaceutical PreparationsIBA
09/2011 - 05/2004
6Proteins (Proteins, Gene)FDA Link
04/2012 - 01/2005
6Transforming Growth Factor beta1 (TGF beta 1)IBA
02/2010 - 02/2003
5Transforming Growth Factors (Transforming Growth Factor)IBA
04/2012 - 01/2005
5Transforming Growth Factor beta3 (TGF beta 3)IBA
08/2009 - 10/2005
4CytokinesIBA
07/2011 - 06/2003
3Prescription DrugsIBA
01/2010 - 05/2004
2Calcitonin Gene-Related PeptideIBA
04/2012 - 03/2011
2NeuropeptidesIBA
04/2012 - 03/2011
2Substance PIBA
04/2012 - 03/2011
2Interleukin-10 (Interleukin 10)IBA
03/2011 - 12/2007
2AntibodiesIBA
12/2006 - 07/2006
2Messenger RNA (mRNA)IBA
01/2006 - 01/2005
2Matrix Metalloproteinases (MMPs)IBA
01/2005 - 01/2003
1Protein Isoforms (Isoforms)IBA
04/2012
1Indicators and Reagents (Reagents)IBA
02/2010
1Reducing AgentsIBA
12/2007
1Biocompatible Materials (Biomaterials)IBA
12/2007
15-bromo-4-chloro-3-indolyl beta-galactoside (X-gal)IBA
03/2007
1Transforming Growth Factor beta2IBA
12/2006
1Fluorescein (Funduscein)FDA LinkGeneric
01/2006
1Smad Proteins (Mothers Against Decapentaplegic Homolog)IBA
01/2006
1Free RadicalsIBA
01/2005
1Collagenases (Collagenase)FDA Link
01/2005
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
05/2004
1Platelet-Derived Growth FactorIBA
05/2004
1Transcription Factors (Transcription Factor)IBA
06/2003
1DNA (Deoxyribonucleic Acid)IBA
02/2003
1EnzymesIBA
02/2003
1Matrix Metalloproteinase 13IBA
01/2003

Therapy/Procedure

8Therapeutics
09/2011 - 06/2007
3Artificial Skin
12/2007 - 10/2006
2Aftercare (After-Treatment)
04/2012 - 03/2011
2Reoperation
07/2011 - 01/2010
2Intradermal Injections
11/2010 - 09/2008
1Denervation
01/2012
1Injections
11/2010